Get the Stockscreener App
3.35
2.62%
-0.09
After Hours:
3.36
0.010
+0.30%
Atea Pharmaceuticals Inc stock is traded at $3.35, with a volume of 186.98K.
It is down -2.62% in the last 24 hours and down -12.99% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$3.44
Open:
$3.41
24h Volume:
186.98K
Relative Volume:
0.84
Market Cap:
$283.24M
Revenue:
$351.37M
Net Income/Loss:
$-135.96M
P/E Ratio:
-2.6172
EPS:
-1.28
Net Cash Flow:
$-85.40M
1W Performance:
-2.90%
1M Performance:
-12.99%
6M Performance:
-17.08%
1Y Performance:
+11.67%
1-Day Range:
$3.34
$3.48
1-Week Range:
$3.34
$3.57
52-Week Range:
$2.765
$4.60
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Almitas Capital LLC Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Metrics That Matter About Atea Pharmaceuticals Inc (NASDAQ: AVIR) - Stocks Register
Jean-Pierre Sommadossi Sells 33,941 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock - MarketBeat
Atea Pharmaceuticals CEO sells over $234k in company stock - Investing.com India
Atea Pharmaceuticals CEO sells over $234k in company stock - Investing.com
Q3 2024 EPS Estimates for Atea Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) & SELLAS Life Sciences Group (NASDAQ:SLS) Critical Analysis - Defense World
Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Rises By 13.7% - MarketBeat
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus - AOL
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus - Yahoo Finance
AVIR’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Atea Pharmaceuticals Shares Fall on Covid-19 Treatment Trial Result - MarketWatch
Atea stock drops as COVID-19 therapy fails in late-stage trial - MSN
Atea stock falls after setback to COVID-19 drug (NASDAQ:AVIR) - Seeking Alpha
Atea Pharmaceuticals reports Phase 3 trial miss for COVID-19 drug - Investing.com
Atea Pharmaceuticals Trial of Covid-19 Treatment Bemnifosbuvir Fails to Meet Primary Endpoint - MarketWatch
Atea Pharmaceuticals Provides Update on Global Phase 3 - GlobeNewswire
Atea Pharmaceuticals Provides Update on Global Phase 3 Rise-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 - Marketscreener.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Acadian Asset Management LLC - Defense World
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - MSN
Atea Pharmaceuticals advances antiviral drug study - Investing.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by SG Americas Securities LLC - Defense World
Atea Pharmaceuticals advances antiviral drug study - Investing.com India
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway - ForexTV.com
Atea Pharmaceuticals Announces Publication of Additional - GlobeNewswire
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway - StockTitan
California State Teachers Retirement System Cuts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Price T Rowe Associates Inc. MD Has $272,000 Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) - MSN
Atea rises after Morgan Stanley upgrade - MSN
Atea stck rises after Morgan Stanley upgrade (NASDAQ:AVIR) - Seeking Alpha
Atea Pharmaceuticals (NASDAQ:AVIR) Upgraded to "Equal Weight" at Morgan Stanley - MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Upgraded by Morgan Stanley to Equal Weight - Defense World
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy - MSN
Q3 2024 Earnings Estimate for Atea Pharmaceuticals, Inc. Issued By William Blair (NASDAQ:AVIR) - MarketBeat
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy - Yahoo Finance
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Holdings Increased by Vanguard Group Inc. - Defense World
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2024 Earnings Call Transcript - Insider Monkey
21,472 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Acquired by Tidal Investments LLC - Defense World
William Blair Weighs in on Atea Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript - Seeking Alpha
Atea Pharmaceuticals (NASDAQ:AVIR) Releases Quarterly Earnings Results, Beats Expectations By $0.28 EPS - Defense World
Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.28 EPS - MarketBeat
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Public Employees Retirement System of Ohio Has $247,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance
Atea Pharmaceuticals (AVIR) Set to Announce Earnings on Wednesday - Defense World
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update - Defense World
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):